A number of firms have modified their ratings and price targets on shares of Pyxis Oncology (NASDAQ: PYXS) recently:
- 11/16/2026 – Pyxis Oncology was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
- 11/7/2026 – Pyxis Oncology was upgraded by Wall Street Zen from “sell” to “hold”.
- 11/6/2026 – Pyxis Oncology had its price target raised by Royal Bank Of Canada from $6.00 to $7.00. They now have an “outperform” rating on the stock.
- 11/6/2026 – Pyxis Oncology had its price target lowered by Wedbush from $8.00 to $7.00. They now have an “outperform” rating on the stock.
- 11/5/2026 – Pyxis Oncology was given a new $5.00 price target by Stifel Nicolaus.
- 9/25/2026 – Pyxis Oncology had its “sell (e+)” rating reaffirmed by Weiss Ratings.
Pyxis Oncology Trading Up 2.1%
NASDAQ PYXS opened at $1.44 on Wednesday. Pyxis Oncology, Inc. has a 1-year low of $1.03 and a 1-year high of $5.55. The company has a 50 day moving average of $2.23 and a 200-day moving average of $2.15. The company has a market cap of $172.24 million, a price-to-earnings ratio of -1.11 and a beta of 1.41.
Pyxis Oncology (NASDAQ:PYXS – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.03. On average, equities research analysts forecast that Pyxis Oncology, Inc. will post -1.12 earnings per share for the current year.
Pyxis Oncology, Inc. is a clinical-stage biotechnology company developing antibody-based medicines for people with difficult-to-treat cancers. Its research focuses on targeted therapies intended to attack tumors while limiting effects on healthy tissue. The company’s pipeline includes PYX-201, an investigational antibody-drug conjugate designed to target EDB+ fibronectin, a protein found in the tumor microenvironment. The program reflects Pyxis Oncology’s broader approach of using antibodies to direct cancer-fighting agents to tumor-associated targets.
Read More
- Five stocks we like better than Pyxis Oncology
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Pyxis Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.
